N
New Equilibrium Biosciences
Drug discovery for intrinsically disordered proteins
About New Equilibrium Biosciences
New Equilibrium Biosciences, founded in 2019, is a biotechnology firm focused on the rational drug design for a class of proteins that have historically been difficult to target. The company was established by Dr. Virginia Burger, who serves as the CEO, and Dr. Peter Tompa, who is the Chair of the Scientific Advisory Board. Dr. Burger's background includes postdoctoral research in intrinsically disordered protein (IDP) biophysics at MIT and leading scientific collaborations at the AI drug discovery company XtalPi. Dr. Tompa is a distinguished professor and researcher who has been instrumental in the IDP field since its emergence, having authored the first monograph on the subject and organized the first conference in the field.
The company's core technology is a computational-experimental platform that merges artificial intelligence with biophysics to analyze intrinsically disordered proteins (IDPs). These shapeshifting proteins lack a fixed structure, which has made them challenging targets for traditional structure-based drug design methods. New Equilibrium's platform aims to reveal previously invisible conformations and transient binding pockets on these IDPs, thereby enabling the design of new drug candidates. By encoding quantum chemistry in AI models and augmenting physics-based simulations, the company can model large protein systems over extended timescales to identify structural details that can inform drug discovery.
New Equilibrium's business model is centered on discovering and developing lead drug candidates to address life-threatening diseases, with a specific focus on cancers and neurodegenerative disorders where IDPs are implicated. The company seeks to accelerate its internal research and development programs while also exploring strategic partnerships with other pharmaceutical and biotechnology organizations. After initial grants from the National Science Foundation and Massachusetts Life Sciences Center, and a pre-seed round from the Petri Life Sciences Incubator, the company secured a significant $10 million seed funding round in 2021 led by RA Capital Management. This capital was intended to scale up its R&D facilities, expand the team, and advance its programs targeting IDPs.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Mar 2021 | $10M | $40M | RA Capital Management · Petri | — |
| SEED✓Equity / VC | Jun 2020 | $250K | $1M | Petri | — |
Growth signals
Latest recorded traffic for New Equilibrium Biosciences is 930 monthly website visits, up 4550% over the last three months. New Equilibrium Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
New Equilibrium Biosciences in the Boston ecosystem
The New Equilibrium Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Massachusetts Life Sciences Center
US National Science Foundation
Petri
RA Capital Management
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about New Equilibrium Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See New Equilibrium Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









